A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly ®), an infliximab biosimilar...

Source: Arthritis Research and Therapy - July 27, 2018 Category: Rheumatology Authors: Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos and K. Lea Sewell Tags: Research article Source Type: research